Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional

Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation

ClinicalTrials.gov ID: NCT00143117

Public ClinicalTrials.gov record NCT00143117. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.

Study identification

NCT ID
NCT00143117
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
460 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2004 (Type not available)
Primary completion
Jun 2005 (Actual)
Completion
Jun 2005 (Actual)
Last update posted
Nov 7, 2012

2004 – 2005

United States locations

U.S. sites
51
U.S. states
23
U.S. cities
51
Facility City State ZIP Site status
Pfizer Investigational Site Tucson Arizona — —
Pfizer Investigational Site Anaheim California — —
Pfizer Investigational Site Atherton California — —
Pfizer Investigational Site Beverly Hills California — —
Pfizer Investigational Site Laguna Woods California — —
Pfizer Investigational Site Newport Beach California — —
Pfizer Investigational Site Redwood City California — —
Pfizer Investigational Site San Diego California — —
Pfizer Investigational Site Tarzana California — —
Pfizer Investigational Site Walnut Creek California — —
Pfizer Investigational Site Aurora Colorado — —
Pfizer Investigational Site Waterbury Connecticut — —
Pfizer Investigational Site Aventura Florida — —
Pfizer Investigational Site New Port Richey Florida — —
Pfizer Investigational Site Pembroke Pines Florida — —
Pfizer Investigational Site Evansville Indiana — —
Pfizer Investigational Site Fort Wayne Indiana — —
Pfizer Investigational Site Indianapolis Indiana — —
Pfizer Investigational Site Michigan City Indiana — —
Pfizer Investigational Site Lexington Kentucky — —
Pfizer Investigational Site Madisonville Kentucky — —
Pfizer Investigational Site Metairie Louisiana — —
Pfizer Investigational Site Milford Massachusetts — —
Pfizer Investigational Site Saint Clair Shores Michigan — —
Pfizer Investigational Site Minneapolis Minnesota — —
Pfizer Investigational Site Southhaven Mississippi — —
Pfizer Investigational Site Kansas City Missouri — —
Pfizer Investigational Site Reno Nevada — —
Pfizer Investigational Site Edison New Jersey — —
Pfizer Investigational Site New Brunswick New Jersey — —
Pfizer Investigational Site Voorhees Township New Jersey — —
Pfizer Investigational Site Albany New York — —
Pfizer Investigational Site Endwell New York — —
Pfizer Investigational Site New York New York — —
Pfizer Investigational Site West Seneca New York — —
Pfizer Investigational Site Williamsville New York — —
Pfizer Investigational Site Charlotte North Carolina — —
Pfizer Investigational Site Durham North Carolina — —
Pfizer Investigational Site Beachwood Ohio — —
Pfizer Investigational Site Tulsa Oklahoma — —
Pfizer Investigational Site Germantown Tennessee — —
Pfizer Investigational Site Knoxville Tennessee — —
Pfizer Investigational Site Memphis Tennessee — —
Pfizer Investigational Site Milan Tennessee — —
Pfizer Investigational Site Dallas Texas — —
Pfizer Investigational Site Fort Worth Texas — —
Pfizer Investigational Site Houston Texas — —
Pfizer Investigational Site Plano Texas — —
Pfizer Investigational Site San Antonio Texas — —
Pfizer Investigational Site Tacoma Washington — —
Pfizer Investigational Site Milwaukee Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00143117, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 7, 2012 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00143117 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →